Real-world Effectiveness of Asciminib and Treatment Patterns in Patients With Chronic Myeloid Leukemia With T315I Mutation - a Chart Review Study of Patients Treated in the Asciminib Managed Access Program (MAP)

简要总结

主要结局

次要结局

• MMR at and by 3, 9, and 12 months(At and by 3, 9, and 12 months)
• Time to first CCyR at and by 3, 6, 9, and 12 months(At and by 3, 6, 9, and 12 months)
• Time from CML diagnosis to study index (i.e., asciminib) start date(Baseline)
• Prior TKIs between CML diagnosis and T315I mutation diagnosis(Baseline)
• Gender(Baseline)
• Complete cytogenic response (CCyR) at and by 3, 6, 9, and 12 months(At and by 3, 6, 9, and 12 months)
• Country of residence(Baseline)
• Complete hematologic response (CHR) at and by 3, 6, 9, and 12 months(At and by 3, 6, 9, and 12 months)
• Number of patients per response type at asciminib start date(Baseline)
• Overall tyrosine kinase inhibitors (TKIs) prior to index date(Baseline)
• Number of patients with intolerance to last TKI prior to asciminib, per category(Baseline)
• Asciminib discontinuation(Up to 13 months)
• Status of CML at baseline(Baseline)
• Stem-cell transplant performed status(Baseline)
• Race(Baseline)
• Medical history by system-organ-class, preferred term from CML diagnosis to asciminib start date(Baseline)
• Number of patients with response to prior TKIs from CML diagnosis to asciminib (index date)(Baseline)
• Asciminib dose(Up to 13 months)
• Duration of exposure to asciminib(Up to 13 months)
• Prior TKIs between T315I mutation diagnosis and index date(Baseline)
• Number of patients with response to prior TKIs between CML diagnosis to T315I mutation diagnosis(Baseline)
• Number of patients with response to prior TKIs between T315I mutation diagnosis to asciminib start (index date)(Baseline)
• Sequence of prior TKI treatment patterns(Baseline)
• Number of patients with intolerance to prior TKIs, per category(Baseline)